These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 1363260)

  • 21. Class III antiarrhythmic agents: the next wave.
    Bauman JL
    Pharmacotherapy; 1997; 17(2 Pt 2):76S-83S; discussion 89S-91S. PubMed ID: 9085343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What have clinical trials taught us about proarrhythmia?
    Skanes AC; Green MS
    Can J Cardiol; 1996 Apr; 12 Suppl B():20B-26B. PubMed ID: 8616725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.
    Boriani G; Lubinski A; Capucci A; Niederle R; Kornacewicz-Jack Z; Wnuk-Wojnar AM; Borggrefe M; Brachmann J; Biffi M; Butrous GS;
    Eur Heart J; 2001 Dec; 22(23):2180-91. PubMed ID: 11913480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
    Hohnloser SH
    Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigational antiarrhythmic drugs for the treatment of ventricular rhythm disturbances.
    Pratt CM; Luck JC; Mann DE; Wyndham CR
    Cardiol Clin; 1984 Feb; 2(1):35-46. PubMed ID: 6443563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [What is the latest in anti-arrhythmia therapy?].
    Gloor HO
    Schweiz Med Wochenschr; 1991 Nov; 121(47):1711-4. PubMed ID: 1720259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 2000 Jan; 15(1):41-53. PubMed ID: 10666660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.
    Hohnloser SH; Singh BN
    J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):920-36. PubMed ID: 8548113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues.
    Wolbrette DL
    Am J Cardiol; 2003 Mar; 91(6A):39D-44D. PubMed ID: 12670641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dofetilide, a new class III antiarrhythmic agent.
    Lenz TL; Hilleman DE
    Pharmacotherapy; 2000 Jul; 20(7):776-86. PubMed ID: 10907968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA; Kluger J; White CM
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs.
    Chen J; Xue Y; Eto K; Ni C; Hashimoto K
    J Cardiovasc Pharmacol; 1996 Oct; 28(4):576-84. PubMed ID: 8891885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent antiarrhythmic drugs.
    Jaillon P; Drici M
    Am J Cardiol; 1989 Dec; 64(20):65J-69J. PubMed ID: 2688391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction.
    Singh BN
    Am J Cardiol; 1990 Sep; 66(9):9C-20C. PubMed ID: 1699400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm.
    Fuchs T; Groysman R; Meilichov I
    Pharmacotherapy; 2008 Jan; 28(1):14-9. PubMed ID: 18154469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and proarrhythmia of oral sotalol in pediatric patients.
    Pfammatter JP; Paul T; Lehmann C; Kallfelz HC
    J Am Coll Cardiol; 1995 Oct; 26(4):1002-7. PubMed ID: 7560592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators.
    Mason JW
    N Engl J Med; 1993 Aug; 329(7):452-8. PubMed ID: 8332150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New aspects of the clinical use of anti-arrhythmia agents with special reference to acute therapy of ventricular tachycardia (lidocaine vs. ajmaline)].
    Manz M; Mletzko R; Jung W; Lüderitz B
    Herz; 1990 Apr; 15(2):79-89. PubMed ID: 2188894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COMBINED PHARMACOLOGICAL THERAPY INCLUDING SEVERAL ANTIARRHYTHMIC AGENTS FOR TREATMENT OF DIFFERENT DISORDERS OF CARDIAC RHYTHM.
    Kapustnick Y; Lutsenko R; Sуdorenko A
    Georgian Med News; 2021 Jun; (315):85-93. PubMed ID: 34365431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiarrhythmic agents for chronic ventricular arrhythmias.
    Nestico PF; Morganroth J
    Compr Ther; 1987 Apr; 13(4):26-35. PubMed ID: 3105950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.